Telavancin.
Publication
, Journal Article
Corey, GR; Stryjewski, ME; Weyenberg, W; Yasothan, U; Kirkpatrick, P
Published in: Nat Rev Drug Discov
December 2009
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Drug Discov
DOI
EISSN
1474-1784
Publication Date
December 2009
Volume
8
Issue
12
Start / End Page
929 / 930
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Staphylococcal Infections
- Skin Diseases, Bacterial
- Randomized Controlled Trials as Topic
- Pharmacology & Pharmacy
- Methicillin-Resistant Staphylococcus aureus
- Lipoglycopeptides
- Humans
- Drug Resistance, Bacterial
Citation
APA
Chicago
ICMJE
MLA
NLM
Corey, G. R., Stryjewski, M. E., Weyenberg, W., Yasothan, U., & Kirkpatrick, P. (2009). Telavancin. Nat Rev Drug Discov, 8(12), 929–930. https://doi.org/10.1038/nrd3051
Corey, G Ralph, Martin E. Stryjewski, Wim Weyenberg, Uma Yasothan, and Peter Kirkpatrick. “Telavancin.” Nat Rev Drug Discov 8, no. 12 (December 2009): 929–30. https://doi.org/10.1038/nrd3051.
Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P. Telavancin. Nat Rev Drug Discov. 2009 Dec;8(12):929–30.
Corey, G. Ralph, et al. “Telavancin.” Nat Rev Drug Discov, vol. 8, no. 12, Dec. 2009, pp. 929–30. Pubmed, doi:10.1038/nrd3051.
Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P. Telavancin. Nat Rev Drug Discov. 2009 Dec;8(12):929–930.
Published In
Nat Rev Drug Discov
DOI
EISSN
1474-1784
Publication Date
December 2009
Volume
8
Issue
12
Start / End Page
929 / 930
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Staphylococcal Infections
- Skin Diseases, Bacterial
- Randomized Controlled Trials as Topic
- Pharmacology & Pharmacy
- Methicillin-Resistant Staphylococcus aureus
- Lipoglycopeptides
- Humans
- Drug Resistance, Bacterial